Study suggests re-examining eligibility criteria for randomized controlled trials of hematologic malignancies.
Takeaways from Cleveland Clinic’s hematology/medical oncology experts
Molecular data enhance traditional scoring systems
Research improving myelodysplastic syndromes treatment
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Complex karyotypes, TET2 mutations lower survival rates
Cleveland Clinic researchers warn against overtreatment
Insurance data analysis uncovers real-world behaviors
Response in patient subgroups shows promise, however
Screening high-risk patients early may be the way to go
Researchers suspect that mutations may be leukemogenic